Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

BACKGROUND: The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Commun (Lond)
Asıl Yazarlar: Oh, Sung Yong, Kim, Won Seog, Kim, Jin Seok, Kim, Seok Jin, Yoon, Dok Hyun, Yang, Deok-Hwan, Lee, Won Sik, Kim, Hyo Jung, Yhim, Ho-Young, Jeong, Seong Hyun, Won, Jong Ho, Lee, Suee, Kong, Jee Hyun, Lim, Sung-Nam, Ji, Jun Ho, Kwon, Kyung A., Lee, Gyeong-Won, Lee, Jae Hoon, Lee, Ho Sup, Shin, Ho-Jin, Suh, Cheolwon
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796378/
https://ncbi.nlm.nih.gov/pubmed/31619290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0403-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller